A5035293166- Liver Disease and Transplantation
- Liver Disease Diagnosis and Treatment
- Organ Transplantation Techniques and Outcomes
- Hepatitis C virus research
- Liver Diseases and Immunity
- Renal Transplantation Outcomes and Treatments
- Hepatitis B Virus Studies
- Clinical Nutrition and Gastroenterology
- Hepatocellular Carcinoma Treatment and Prognosis
- Drug-Induced Hepatotoxicity and Protection
- Organ Donation and Transplantation
- Organ and Tissue Transplantation Research
- Alcohol Consumption and Health Effects
- Transplantation: Methods and Outcomes
- Pediatric Hepatobiliary Diseases and Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- HIV/AIDS drug development and treatment
- Gastroesophageal reflux and treatments
- Palliative Care and End-of-Life Issues
- Lysosomal Storage Disorders Research
- Pancreatitis Pathology and Treatment
- Pharmacological Effects and Toxicity Studies
- Metabolism and Genetic Disorders
- Esophageal and GI Pathology
- Immunodeficiency and Autoimmune Disorders
Icahn School of Medicine at Mount Sinai
2016-2025
Mount Sinai Health System
2025
Mount Sinai Hospital
2013-2024
Mount Sinai Hospital
2015-2024
Mount Sinai Medical Center
2015-2024
University of California, Los Angeles
2006-2023
Xiangya Hospital Central South University
2022
Central South University
2022
University Gastroenterology
2022
GTx (United States)
2021
As the population that is infected with hepatitis C virus (HCV) ages, number of patients decompensated cirrhosis expected to increase.We conducted a phase 3, open-label study involving both previously treated and untreated HCV genotypes 1 through 6 who had (classified as Child-Pugh-Turcotte class B). Patients were randomly assigned in 1:1:1 ratio receive nucleotide polymerase inhibitor sofosbuvir NS5A velpatasvir once daily for 12 weeks, sofosbuvir-velpatasvir plus ribavirin or 24 weeks. The...
The Banff Working Group on Liver Allograft Pathology reviewed and discussed literature evidence regarding antibody-mediated liver allograft rejection at the 11th (Paris, France, June 5-10, 2011), 12th (Comandatuba, Brazil, August 19-23, 2013), 13th (Vancouver, British Columbia, Canada, October 2015) meetings of Conference Pathology. Discussion continued online. primary goal was to introduce guidelines consensus criteria for diagnosis provide a comprehensive update all Schema recommendations....
<h3>Background & Aims</h3> Patients with detectable hepatitis C virus (HCV) RNA at the time of liver transplantation universally experience recurrent HCV infection. Antiviral treatment before can prevent recurrence, but existing interferon-based regimens are poorly tolerated and either ineffective or contraindicated in most patients. We performed a trial to determine whether sofosbuvir ribavirin could recurrence afterward. <h3>Methods</h3> In phase 2, open-label study, 61 patients any...
Early liver transplantation (LT) in European centers reportedly improved survival patients with severe alcoholic hepatitis (AH) not responding to medical therapy. Our aim was determine if a strategy of early LT for AH could be applied successfully the United States. We reviewed 111 at our center from January 2012 2015. The primary end point mortality 6 months or LT, secondary alcohol relapse after LT. Survival compared between those receiving and matched who did not. Using process similar...
The coronavirus disease 2019 (COVID‐19) pandemic has had a tremendous global impact since it began in November of 2019. However, there are concerns that the COVID‐19 will not affect all equally and some populations be particularly vulnerable. Relevant to liver disease, patients with alcohol use disorder (AUD) alcohol‐associated (ALD) may among most severely impacted. reasons for this include being at higher risk severe infection due depressed immune system high‐risk underlying comorbidities,...
•Novel treatments for PSC are an urgent unmet need.•This phase II study evaluated OCA in patients with PSC.•OCA 5–10 mg significantly reduced serum ALP levels at 24 weeks.•The safety profile of was consistent previous studies. Background & AimsPrimary sclerosing cholangitis (PSC) is a rare, cholestatic liver disease no currently approved therapies. Obeticholic acid (OCA) potent farnesoid X receptor (FXR) agonist the treatment primary biliary cholangitis. We investigated efficacy and...
A few case reports of autoimmune hepatitis-like liver injury have been reported after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. We evaluated clinical features, treatment response and outcomes following SARS-CoV-2 vaccination in a large series.We collected data from cases 18 countries. The type was assessed with the R-value. study population categorized according to features immune-mediated hepatitis (positive autoantibodies elevated immunoglobulin G levels)...
Objective To summarize the evolution of a living donor liver transplant program and authors’ experience with 109 cases. Summary Background Data The institution began to offer transplants children in 1993 adults 1998. Methods Donors were healthy, ages 18 60 years, related or unrelated, ABO-compatible (except one case). Donor evaluation was thorough. Liver biopsy performed for abnormal lipid profiles history significant alcohol use, body mass index more than 28, suspected steatosis. Imaging...
Primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are uncommon liver diseases of unknown etiology. Reported clustering PBC cases may be due to environmental factors. Individuals with have a high prevalence thyroid disease is reportedly more prevalent near Superfund toxic waste sites (SFS). The objective this study was examine the potential individuals PSC SFS. De-identified clinical demographic data were used determine observed for each New York City zip code (n = 174)...
Hepatitis C virus (HCV) is a controversial indication for liver transplantation (LT) in human immunodeficiency (HIV)-infected patients because of reportedly poor outcomes. This prospective, multicenter US cohort study compared patient and graft survival 89 HCV/HIV-coinfected 2 control groups: 235 HCV-monoinfected LT controls all transplant recipients who were 65 years old or older. The 3-year rates 60% [95% confidence interval (CI) = 47%-71%] 53% (95% CI 40%-64%) the HCV/HIV 79% 72%-84%) 74%...
Chronic hepatitis C is the most common indication for liver transplantation, but viral recurrence universal and progressive graft injury occurs in recipients. Our aim was to assess safety, pharmacokinetics (PK), antiviral effects of high doses a human antibody enriched immune globulin product (HCIG) patients undergoing transplantation chronic C. This multicenter, randomized, open-label, controlled trial conducted at 4 transplant centers United States. A total 18 with C, who underwent were...
Liver cirrhosis is a major risk factor in general surgery. Few studies have reported on the outcome of cardiac surgery these patients. Herein we report our recent experience this high-risk patient population according to Child-Turcotte-Pugh classification and Model for End-Stage Disease (MELD) score. Between January 1998 December 2004, 27 patients (mean age 58 ± 10 yr, 20 male) with who underwent were identified. Patients class A (n = 10), B 11), C 6) mean MELD score was 14.2 4.2. Operative...
Background Non-alcoholic steatohepatitis (NASH) and resultant liver fibrosis is a major health problem without approved pharmacotherapy. Pre-clinical results of GR-MD-02, galectin-3 inhibitor, suggested potential efficacy in NASH with advanced fibrosis/cirrhosis prompted initiation clinical development programme fibrosis. Aim To evaluate the safety, pharmacokinetics exploratory pharmacodynamic markers GR-MD-02 subjects having bridging Methods The GT-020 study was first-in-human, sequential...
Resistant bacterial infections are important causes of morbidity and mortality after liver transplantation (LT). This was a retrospective cohort study evaluating the outcomes associated with carbapenem-resistant Klebsiella pneumoniae (CRKP) LT. In 2005-2006 175 consecutive LT recipients, 91 infection episodes were observed in 61 patients (35%). The rate 1 year 18% (32/175). Enterococcus (43%) species (37%) most frequently isolated bacteria. CRKP occurred 14 patients, 10 these (71%) died....
Nonadherence to immunosuppressants may play a role in late rejection liver transplant recipients. In children, emerging data suggest that adherence can be measured through the computation of standard deviation (SD) consecutive blood levels tacrolimus, which results number reflects degree variability between individual measures: medication level index (MLVI). A higher MLVI value means erratic immunosuppression, likely due less adherence. Data on this method are limited for adults. We obtained...
Abstract Guidelines currently favor vitamin K antagonists or low-molecular-weight heparins for treatment of noncirrhotic portal vein thrombosis (ncPVT). Use direct oral anticoagulants (DOACs) in PVT has been met with concern because the lack data. We conducted a retrospective study to investigate efficacy and safety DOACs ncPVT, compare them standard therapies: 330 patients followed-up mean 41.6 months, received warfarin (n = 108), enoxaparin 70), rivaroxaban 65), apixaban 20), dabigatran...